Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | POLE4 | CTRPv2 | pan-cancer | AAC | -0.14 | 1e-05 |
mRNA | MVB12B | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
mRNA | LAMTOR1 | CTRPv2 | pan-cancer | AAC | -0.14 | 1e-05 |
mRNA | GIGYF1 | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
mRNA | C3orf62 | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
mRNA | IGF2BP2 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
mRNA | SPATS2L | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
mRNA | ZNF286A | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
mRNA | PPP1R3D | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
mRNA | LGALS3 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |